Tags

Type your tag names separated by a space and hit enter

Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
Expert Rev Vaccines. 2015; 14(8):1149-57.ER

Abstract

BACKGROUND

Varicella is a highly infectious childhood disease. Tetravalent measles-mumps-rubella-varicella (MMRV) vaccine was introduced as one-syringe dose.

OBJECTIVE

To evaluate the immunogenicity and reactogenicity of MMRV vaccine versus trivalent MMR with varicella (V) vaccines in healthy children and to assess the respective safety issue.

METHODS

Randomized controlled trials (RCTs) were searched from the OVID databases. Trials were eligible if healthy children were randomized to receive MMRV or MMR+V vaccine. Seroconversions in serum antibody titers were the primary outcomes; adverse events were the secondary outcomes.

RESULTS

Ten RCTs with 8961 healthy children were identified. MMRV and MMR+V vaccines showed comparable immunogenicity against measles (relative risk [RR] = 0.99, 95% CI = 0.98-1.00), mumps (RR = 0.99, 95% CI = 0.97-1.00), rubella (RR = 1.00, 95% CI = 1.00-1.01) and varicella (RR = 0.98, 95% CI = 0.95-1.01). At least 93% of children in both groups had seroconverted within 6 weeks. MMRV group showed significantly higher incidences of fever (RR = 1.19, 95% CI = 1.09-1.31) and rash (RR = 1.23, 95% CI = 1.06-1.43).

CONCLUSIONS

The immunogenicities of MMRV and MMR+V vaccines were comparable in healthy children; however, MMRV vaccination showed higher incidences of fever and rash.

Authors+Show Affiliations

School of Public Health and Primary Care, China.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

26081133

Citation

Leung, Julia Hy, et al. "Immunogenicity and Reactogenicity of Tetravalent Vaccine for Measles, Mumps, Rubella and Varicella (MMRV) in Healthy Children: a Meta-analysis of Randomized Controlled Trials." Expert Review of Vaccines, vol. 14, no. 8, 2015, pp. 1149-57.
Leung JH, Hirai HW, Tsoi KK. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials. Expert Rev Vaccines. 2015;14(8):1149-57.
Leung, J. H., Hirai, H. W., & Tsoi, K. K. (2015). Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials. Expert Review of Vaccines, 14(8), 1149-57. https://doi.org/10.1586/14760584.2015.1057572
Leung JH, Hirai HW, Tsoi KK. Immunogenicity and Reactogenicity of Tetravalent Vaccine for Measles, Mumps, Rubella and Varicella (MMRV) in Healthy Children: a Meta-analysis of Randomized Controlled Trials. Expert Rev Vaccines. 2015;14(8):1149-57. PubMed PMID: 26081133.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials. AU - Leung,Julia Hy, AU - Hirai,Hoyee W, AU - Tsoi,Kelvin Kf, Y1 - 2015/06/16/ PY - 2015/6/18/entrez PY - 2015/6/18/pubmed PY - 2016/4/16/medline KW - immunogenicity KW - measles–mumps–rubella KW - reactogenicity KW - tetravalent vaccine KW - varicella SP - 1149 EP - 57 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 14 IS - 8 N2 - BACKGROUND: Varicella is a highly infectious childhood disease. Tetravalent measles-mumps-rubella-varicella (MMRV) vaccine was introduced as one-syringe dose. OBJECTIVE: To evaluate the immunogenicity and reactogenicity of MMRV vaccine versus trivalent MMR with varicella (V) vaccines in healthy children and to assess the respective safety issue. METHODS: Randomized controlled trials (RCTs) were searched from the OVID databases. Trials were eligible if healthy children were randomized to receive MMRV or MMR+V vaccine. Seroconversions in serum antibody titers were the primary outcomes; adverse events were the secondary outcomes. RESULTS: Ten RCTs with 8961 healthy children were identified. MMRV and MMR+V vaccines showed comparable immunogenicity against measles (relative risk [RR] = 0.99, 95% CI = 0.98-1.00), mumps (RR = 0.99, 95% CI = 0.97-1.00), rubella (RR = 1.00, 95% CI = 1.00-1.01) and varicella (RR = 0.98, 95% CI = 0.95-1.01). At least 93% of children in both groups had seroconverted within 6 weeks. MMRV group showed significantly higher incidences of fever (RR = 1.19, 95% CI = 1.09-1.31) and rash (RR = 1.23, 95% CI = 1.06-1.43). CONCLUSIONS: The immunogenicities of MMRV and MMR+V vaccines were comparable in healthy children; however, MMRV vaccination showed higher incidences of fever and rash. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/26081133/Immunogenicity_and_reactogenicity_of_tetravalent_vaccine_for_measles_mumps_rubella_and_varicella__MMRV__in_healthy_children:_a_meta_analysis_of_randomized_controlled_trials_ L2 - https://www.tandfonline.com/doi/full/10.1586/14760584.2015.1057572 DB - PRIME DP - Unbound Medicine ER -